On November 22, 2022 EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a Norwegian clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, and the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, reported the publication of a paper in the peer-reviewed Journal of Controlled Release titled "Effect of Acoustic Cluster Therapy combined with chemotherapy in a mouse model of pancreatic cancer" (Press release, Exact Therapeutics, NOV 22, 2022, View Source [SID1234624334]). This study was partly funded by a grant from Innovation Norway.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ACT technology is based on microclusters of microbubble-microdroplets and when sonicated, vaporisation of the microdroplets lead to the formation of larger ACT bubbles. The formation and subsequent oscillation of the ACT bubbles in the microvasculature produces mechanical bio-effects that enhance drug delivery and efficacy. TGen have evaluated the effectiveness of the technology in a preclinical pancreatic cancer model, and the results demonstrated that ACT significantly improved the therapeutic efficacy of two cornerstone treatment regimens in the management of pancreatic cancer. The best effect was seen when drug administration preceded the ACT treatment, but interestingly the anti-tumour effect was almost maintained when the drugs were administered after ACT-treatment was finalized. Similar observations have been made in previous work with ACT combined with chemotherapy. This suggests that the main effect of ACT is not on the drug itself, but rather affects the vasculature and tumour microenvironment to facilitate drug delivery and therapeutic response.
For the full article, please follow: https://www.sciencedirect.com/science/article/pii/S016836592200760X
"Our study demonstrates that ACT can significantly improve the effect of two standard of care chemotherapeutic regimens in a patient-derived pancreatic cancer model in mice. The ACT treatment resulted in a significant increase in tumour growth inhibition and a 7.2 times higher probability of having a complete remission of the tumour compared to the chemotherapeutics alone." said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and the study’s senior author.
"Pancreatic cancer is known to be notoriously resistant to treatment, in part because of poor drug delivery." said Dr. Daniel Von Hoff, TGen’s Distinguished Professor and one of the national’s lead experts in pancreatic cancer. "The results from the study are some of the most encouraging ones we have seen in preclinical models for pancreatic cancer, and we look forward to being involved in the further development of this promising technology."
Dr Per Walday, CEO of EXACT-Tx, commented: "We are very pleased to announce the publication of these encouraging results from our collaboration with the prestigious Translational Genomics Research Institute in Phoenix, Arizona. These data are produced in a model with patient-derived material, which more closely resembles the tumour tissue characteristics of pancreatic cancer in man compared to cell-line based models. The results further underpin the established potential of ACT to enhance standard of care treatments for difficult to treat cancers and we look forward to progressing our clinical development program in this area."